-- 根據FactSet調查的分析師報告，Kymera Therapeutics (KYMR) 的平均評級為“買入”，平均目標價為118.27美元。 （報道北美、亞洲和歐洲主要銀行及研究機構的股票、商品和經濟研究。研究機構可透過以下連結聯絡我們：https://www..com/contact-us）
Related Articles
Research
Research Alert: Bio-techne: U.s. Academia Grows Modestly, Q3 Fy 26 Eps Meets Consensus
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Bio-Techne delivered Q3 FY 26 (Jun.) adjusted EPS of $0.53, in-line with consensus, while sales declined 2% to $311.4M amid challenging conditions and unfavorable Commercial Supply timing. Double-digit pharma growth for the sixth consecutive quarter helped offset the gradually recovering biotech funding environment. We believe the company's diversified portfolio and strong financial flexibility position Bio-Techne to capitalize on improving market conditions. Management expressed cautious optimism about improving end-market fundamentals, noting early indicators of better alignment between biotech funding and customer purchasing. U.S. academic markets showed stabilization with low-single-digit growth, representing improvement from recent weakness. Protein Sciences revenue declined 1% to $226.2M with 44.2% operating margin, while Diagnostics and Spatial Biology revenue fell 4% to $85.6M but operating margin improved to 12.1% following the Exosome divestiture.
$TECH
Research
Research Alert: Apo Delivers Strong Q1 2026 Results With Record Fee-related Earnings
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:APO delivered strong Q1 2026 results with record fee-related earnings of $728M (+30% Y/Y) and adjusted net income of $1.94 per share. Total AUM surpassed the $1T milestone at $1.026T (+31% Y/Y) due to record inflows of $115B, while fee-generating AUM was $836B (+40% Y/Y). We think the ALT investment cycle is accelerating with higher private equity monetization activity, positioning APO as a market leader in private credit. Even with negative media on private credit, APO's Credit segment realized $108B in quarterly inflows and outflow of $20B. APO did not provide specific 2026 guidance, but trends are favorable, in our view. Management fees grew 24% Y/Y to $952M, with perpetual capital representing 60% of total AUM. We think APO is well-positioned for accelerated performance fee monetization with $74B in dry powder and superior credit quality at 11 bps losses versus 12 bps industry average. The firm returned $1.5B to shareholders through dividends and repurchases while implementing a new $4.0B buyback program.
$APO
Sectors
Sector Update: Energy Stocks Fall Pre-Bell Wednesday
Energy stocks were lower premarket Wednesday, with the State Street Energy Select Sector SPDR ETF (XLE) retreating by 4%.The United States Oil Fund (USO) was down 7.5%, while The United States Natural Gas Fund (UNG) was 1.4% lower.Front-month US West Texas Intermediate crude oil was down 10% at $91.80 per barrel at the New York Mercantile Exchange. Global benchmark North Sea Brent crude oil fell 9.6% to $99.34 per barrel, and natural gas futures were 2.5% lower at $2.72 per 1 million British Thermal Units.TotalEnergies (TTE) shares were down more than 4% before the opening bell, reversing the 1.4% gain from the prior session. The company said it signed an agreement with Dell Technologies (DELL) and Nvidia (NVDA) to design and install its next high-performance supercomputer, called Pangea 5, in southern France.Equinor (EQNR) shares were down more than 8% premarket after the company reported lower Q1 revenue.Select Water Solutions (WTTR) stock was up over 4% after the company reported better-than-expected Q1 earnings and revenue.
$EQNR$TTE$UNG$USO$WTTR$XLE